The disease is found too late to change its course.
By the time most neurodegenerative disease is diagnosed, the underlying damage has been building for years. The tools to find it earlier have been invasive, slow and expensive. That is the gap.
Sources: WHO; Alzheimer’s Disease International, World Alzheimer Report; Grand View Research (2026).
The conditions on our roadmap.
The platform starts with the indications where digital biomarkers have the strongest published basis, and is built to extend from there.
Alzheimer's disease
The primary indication, and the focus of our largest evidence effort.
Parkinson's disease
Addressed through the equilibrium and movement-related biomarker streams.
Frontotemporal degeneration
A planned expansion indication on the same platform architecture.
Other neurodegenerative disease
The platform is designed to extend to further indications with new training data.
Earlier detection changes what is possible.
The earlier a neurocognitive change is seen, the more options remain: lifestyle intervention, monitoring, treatment, and planning. Detection timing is not a detail. It is the whole point.
A category the market is moving toward.
Source: Grand View Research, digital biomarkers market (2026). Figures are third-party market estimates.